title: Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria.
abstract: Acute intermittent porphyria (AIP) is a human disease resulting from a dominantly inherited partial deficiency of the heme biosynthetic enzyme, porphobilinogen deaminase (PBGD). The frequency of the trait for AIP is 1/10,000 in most populations, but may be markedly higher (1/500) in psychiatric patients. The clinical expression of the disease is characterized by acute, life-threatening attacks of 'porphyric neuropathy' that include abdominal pain, motor and sensory neurological deficits and psychiatric symptoms. Attacks are frequently precipitated by drugs, alcohol and low caloric intake. Identical symptoms occur in other hepatic porphyrias. To study the pathogenesis of the neurologic symptoms of AIP we have generated Pbgd-deficient mice by gene targeting. These mice exhibit the typical biochemical characteristics of human AIP, notably, decreased hepatic Pbgd activity, increased delta-aminolevulinic acid synthase activity and massively increased urinary excretion of the heme precursor, delta-aminolevulinic acid after treatment with drugs such as phenobarbital. Behavioural tests reveal decreased motor function and histopathological findings include axonal neuropathy and neurologic muscle atrophy.
authors.affiliation: Department of Pharmacology, University of Basel, Switzerland.
authors.forename: R L
authors.initials: RL
authors.lastname: Lindberg
authors.forename: C
authors.initials: C
authors.lastname: Porcher
authors.forename: B
authors.initials: B
authors.lastname: Grandchamp
authors.forename: B
authors.initials: B
authors.lastname: Ledermann
authors.forename: K
authors.initials: K
authors.lastname: Bürki
authors.forename: S
authors.initials: S
authors.lastname: Brandner
authors.forename: A
authors.initials: A
authors.lastname: Aguzzi
authors.forename: U A
authors.initials: UA
authors.lastname: Meyer
mesh_terms: D000622:Aminolevulinic Acid / Q000652:urine; D000818:Animals; D001284:Atrophy; D001369:Axons / Q000473:pathology; D001483:Base Sequence; D002678:Chimera; D004195:Disease Models, Animal; D005260:Female; D018390:Gene Targeting; D006801:Humans; D011163:Hydroxymethylbilane Synthase / Q000235:genetics; D007668:Kidney / Q000187:drug effects; D008099:Liver / Q000737:chemistry; D008297:Male; D051379:Mice; D008969:Molecular Sequence Data; D009043:Motor Activity; D018482:Muscle, Skeletal / Q000473:pathology; D009422:Nervous System Diseases / Q000201:enzymology / Q000209:etiology* / Q000235:genetics / Q000473:pathology; D010634:Phenobarbital / Q000494:pharmacology; D017118:Porphyria, Acute Intermittent / Q000201:enzymology / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D012333:RNA, Messenger / Q000032:analysis
chemical_list: D012333:RNA, Messenger; D000622:Aminolevulinic Acid; D011163:Hydroxymethylbilane Synthase; D010634:Phenobarbital